HAEHaemonetics Corporation

$118.73+135% 1Y

Is the business good?

Mixed

The checks split: 7 of 9 health tests passed and earnings fully cash-backed (2.8×), but margins compressing.

2 good, 1 to watch, 1 neutral
Fundamental health (F-score)7 / 9SEC EDGAR · Mar 28, 2026

High fundamental quality. Nine pass/fail tests of year-over-year health from the filings.

Profits arrive as cash2.77×derived · Jun 27, 2026

Operating profit is fully backed by cash. Conversion is improving vs a year ago.

Margin direction, 3 years−2.7 pts

Operating margin has narrowed over the past few years, profitability per dollar of sales is eroding.

Where ROE comes from6% ROA

A balanced mix of margins, efficiency, and leverage. ROE 16% = margin × turnover × leverage.

Unless marked, from derived.

Against the whole market›

Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.

FCF conversiontop 4% of the market
Leverage (Debt/EBITDA)behind 71% of the market

Where this answer is blind. The F-score rewards improvement, so an already-elite company can score mid-pack.

How good a business is HAE?

Haemonetics Corporation earns 7.1% on the capital it employs against a 9.0% cost of capital, so growth costs more than it returns.

7.1%

Return on invested capital · cost of capital 9.0% · 1.9 points below what the capital costs: growth destroys value

Operating margin
12%

Operating margin · Medical Devices median 2.1% · 12 months to Q1 2027

Cash conversion
2.77×

Cash conversion · 1.24× a year ago · operating cash flow covers the operating profit after tax

Share count, year on year
−5.5%

Share count, year on year · bought back, each share owns more of the company

Operating margin by fiscal year
YearOperating margin
FY202110%
FY20228.1%
FY202313%
FY202413%
FY202516%
FY202612%
Details›
Gross margin12 months to Q1 2027
59%
Operating margin12 months to Q1 2027
12%
Net margin12 months to Q1 2027
7.1%
Free cash flow margin
22%
R&D as % of revenue
4.4%
Revenue, trailing twelve months
$1.35B
Free cash flow, trailing twelve months
$291M
Net income, trailing twelve months
$96M
Return on invested capitaloperating profit after tax ÷ debt + equity − cash
7.1%

Margins, capital and share counts from the statements as filed with the SEC; cash conversion is operating cash flow over operating profit after tax.